VIDEO: Studies on early-relapse multiple myeloma treatment highlighted at ASH
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.
In one study, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) outperformed carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma.
"That's not surprising at all; I think that triplets are better than doublets even in the relapse setting," Banerjee, an assistant professor at the University of Washington, said. "Even for patients who had a lousy response to the first line of therapy, they could get on average at least 2 years of benefit out of Isa-Kd in the second-line or third-line setting."
In contrast, median progression-free survival in a study of idecabtagene vicleucel was “unfortunate,” Banerjee said.
Subjects in the study were culled from a cohort in the KarMMa-2A study. The patients were high-risk with early relapse after receiving frontline autologous stem cell transplantation.
Even though PFS was less than 1 year, there was a solid response rate, Banerjee said.
References:
- Martin T, et al. Abstract 753. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
- Patel K, et al. Abstract 361. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Collapse
Healio Interviews